Literature DB >> 23315315

Is frequent CD4+ T-lymphocyte count monitoring necessary for persons with counts >=300 cells/μL and HIV-1 suppression?

Howard B Gale1, Steven R Gitterman, Heather J Hoffman, Fred M Gordin, Debra A Benator, Ann M Labriola, Virginia L Kan.   

Abstract

Among patients infected with human immunodeficiency virus (HIV), those with HIV-1 RNA <200 copies/mL and CD4 counts ≥300 cells/µL had a 97.1% probability of maintaining durable CD4 ≥200 cells/µL for 4 years. When non-HIV causes of CD4 lymphopenia were excluded, the probability rose to 99.2%. Our data support less frequent CD4 monitoring during viral suppression.

Entities:  

Mesh：

Year:  2013        PMID： 23315315      PMCID： PMC3693489          DOI： 10.1093/cid/cit004

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  9 in total

1.  CD4+ T lymphocyte recovery in individuals with type 1 human immunodeficiency virus infection.

Authors:  Franco Maggiolo; Sebastiano Leone
Journal:  Clin Infect Dis       Date:  2010-08-15       Impact factor: 9.079

2.  Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?

Authors:  Amanda Mocroft; Peter Reiss; Ole Kirk; Cristina Mussini; Enrico Girardi; Philippe Morlat; Christoph Stephan; Stephane De Wit; Katja Doerholt; Jade Ghosn; Heiner C Bucher; Jens D Lundgren; Genevieve Chene; Jose M Miro; Hansjakob Furrer
Journal:  Clin Infect Dis       Date:  2010-09-01       Impact factor: 9.079

3.  Product-limit survival functions with correlated survival times.

Authors:  R L Williams
Journal:  Lifetime Data Anal       Date:  1995       Impact factor: 1.588

4.  Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures.

Authors:  Maria Paola Trotta; Alessandro Cozzi-Lepri; Adriana Ammassari; Jacopo Vecchiet; Giovanni Cassola; Pietro Caramello; Vincenzo Vullo; Fabrizio Soscia; Alessandro Chiodera; Nicoletta Ladisa; Clara Abeli; Roberto Cauda; Anna Rita Buonuomi; Andrea Antinori; Antonella d'Arminio Monforte
Journal:  Clin Infect Dis       Date:  2010-08-15       Impact factor: 9.079

5.  Quantification of the variation due to laboratory and physiologic sources in CD4 lymphocyte counts of clinically stable HIV-infected individuals.

Authors:  J M Raboud; L Haley; J S Montaner; C Murphy; M Januszewska; M T Schechter
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1995

6.  Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.

Authors:  Matthias Egger; Margaret May; Geneviève Chêne; Andrew N Phillips; Bruno Ledergerber; François Dabis; Dominique Costagliola; Antonella D'Arminio Monforte; Frank de Wolf; Peter Reiss; Jens D Lundgren; Amy C Justice; Schlomo Staszewski; Catherine Leport; Robert S Hogg; Caroline A Sabin; M John Gill; Bernd Salzberger; Jonathan A C Sterne
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

7.  Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America.

Authors:  Jonathan E Kaplan; Constance Benson; King K Holmes; John T Brooks; Alice Pau; Henry Masur
Journal:  MMWR Recomm Rep       Date:  2009-04-10

8.  T-lymphocyte subsets in acute illness.

Authors:  C Feeney; S Bryzman; L Kong; H Brazil; R Deutsch; L C Fritz
Journal:  Crit Care Med       Date:  1995-10       Impact factor: 7.598

9.  Sources of variability in repeated T-helper lymphocyte counts from human immunodeficiency virus type 1-infected patients: total lymphocyte count fluctuations and diurnal cycle are important.

Authors:  J L Malone; T E Simms; G C Gray; K F Wagner; J R Burge; D S Burke
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990
  9 in total
  35 in total

1.  Is CD4 monitoring needed among ugandan clients achieving a virologic and immunologic response to treatment?

Authors:  Steven J Reynolds; Joseph B Sempa; Agnes N Kiragga; Kevin Newell; Gertrude Nakigozi; Ronald Galiwango; Ron Gray; Thomas C Quinn; David Serwadda; Larry Chang
Journal:  AIDS Patient Care STDS       Date:  2014-10-07       Impact factor: 5.078

2.  CD4 measurement in a 54-year-old man with sustained HIV-1 viral suppression.

Authors:  Allan Yan; Jerome A Leis; Wayne L Gold
Journal:  CMAJ       Date:  2016-03-29       Impact factor: 8.262

Review 3.  Miniaturized devices for point of care molecular detection of HIV.

Authors:  Michael Mauk; Jinzhao Song; Haim H Bau; Robert Gross; Frederic D Bushman; Ronald G Collman; Changchun Liu
Journal:  Lab Chip       Date:  2017-01-31       Impact factor: 6.799

4.  Implementation and Operational Research: Effects of CD4 Monitoring Frequency on Clinical End Points in Clinically Stable HIV-Infected Patients With Viral Suppression.

Authors:  Jin Young Ahn; David Boettiger; Matthew Law; Nagalingeswaran Kumarasamy; Evy Yunihastuti; Romanee Chaiwarith; Man Po Lee; Benedict L H Sim; Shinichi Oka; Wingwai Wong; Adeeba Kamarulzaman; Pacharee Kantipong; Praphan Phanuphak; Oon Tek Ng; Sasisopin Kiertiburanakul; Fujie Zhang; Sanjay Pujari; Rossana Ditangco; Winai Ratanasuwan; Tuti Parwati Merati; Vonthanak Saphonn; Annette H Sohn; Jun Yong Choi
Journal:  J Acquir Immune Defic Syndr       Date:  2015-07-01       Impact factor: 3.731

5.  Impact of hepatitis coinfection on healthcare utilization among persons living with HIV.

Authors:  Trevor A Crowell; Stephen A Berry; John A Fleishman; Richard W LaRue; Philip T Korthuis; Ank E Nijhawan; Richard D Moore; Kelly A Gebo
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-01       Impact factor: 3.731

6.  Frequency and impact of suboptimal immune recovery on first-line antiretroviral therapy within the International Epidemiologic Databases to Evaluate AIDS in East Africa.

Authors:  Damalie Nakanjako; Agnes N Kiragga; Beverly S Musick; Constantin T Yiannoutsos; Kara Wools-Kaloustian; Lameck Diero; Patrick Oyaro; Emanuel Lugina; John C Ssali; Andrew Kambugu; Philippa Easterbrook
Journal:  AIDS       Date:  2016-07-31       Impact factor: 4.177

7.  Laboratory Measures as Proxies for Primary Care Encounters: Implications for Quantifying Clinical Retention Among HIV-Infected Adults in North America.

Authors:  Peter F Rebeiro; Keri N Althoff; Bryan Lau; John Gill; Alison G Abraham; Michael A Horberg; Mari M Kitahata; Baligh R Yehia; Hasina Samji; John T Brooks; Kate Buchacz; Sonia Napravnik; Michael J Silverberg; Anita Rachlis; Kelly A Gebo; Timothy R Sterling; Richard D Moore; Stephen J Gange
Journal:  Am J Epidemiol       Date:  2015-11-17       Impact factor: 4.897

8.  A Brief Chronicle of CD4 as a Biomarker for HIV/AIDS: A Tribute to the Memory of John L. Fahey.

Authors:  Jonathan M Kagan; Ana M Sanchez; Alan Landay; Thomas N Denny
Journal:  For Immunopathol Dis Therap       Date:  2015

9.  Potential savings by reduced CD4 monitoring in stable patients with HIV receiving antiretroviral therapy.

Authors:  Emily P Hyle; Paul E Sax; Rochelle P Walensky
Journal:  JAMA Intern Med       Date:  2013-10-14       Impact factor: 21.873

10.  Reducing CD4 Monitoring in Children on Antiretroviral Therapy With Virologic Suppression.

Authors:  Mary-Ann Davies; Nathan Ford; Helena Rabie; Geoffrey Fatti; Kathryn Stinson; Janet Giddy; Frank Tanser; Karl-Günter Technau; Shobna Sawry; Brian Eley; Robin Wood; Lynne M Mofenson; Olivia Keiser; Andrew Boulle
Journal:  Pediatr Infect Dis J       Date:  2015-12       Impact factor: 2.129
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.